A

HTA ID Drug Brand Indication Assessment status Date
- Abatacept Orencia® In combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor. NCPE Assessment Process Complete 11th November 2013
20033 Abemaciclib Verzenios® For the treatment of women with hormone receptor positive , human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. Rapid Review Complete 27th July 2020
22020 Abemaciclib Verzenios® in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence. NCPE assessment ongoing 10th May 2023
- Abiraterone Acetate Zytiga® Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy. NCPE Assessment Process Complete 22nd May 2012
- Abiratone Zytiga® Treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated NCPE Assessment Process Complete 7th March 2014
- Abiraterone acetate Zytiga® Treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). No HTA dossier submitted 15th November 2018
21056 Abrocitinib Cibinqo® For the treatment of moderate-to-severe atopic dermatitis in adults aged 18 years and older who are candidates for systemic therapy. Rapid Review Complete 23rd December 2021
20063 Acalabrutinib Calquence® For the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and as monotherapy for the treatment of adult patients with CLL who have received at least one prior therapy. Rapid Review Complete 4th February 2021
23012 Acalabrutinib Calquence® Indicated as monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The Applicant is seeking reimbursement in a subgroup of the licensed population: as monotherapy for previously untreated CLL without 17P deletion or TP53 mutation, in adult patients unsuitable for chemoimmunotherapy and venetoclax in combination with obinutuzumab. Rapid Review Complete 31st March 2023
- Aceclofenac Vitafen® For the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Rapid Review Complete 24th January 2017
- Aclidinium bromide Eklira Genuair® For treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). (Maintenance bronchodilator) Rapid Review Complete 26th October 2012
- Aclidinium bromide/formoterol fumarate dihydrate Brimica®/Genuair® For treatment to relieve symptoms in adult patients with COPD. (Maintenance bronchodilator) Rapid Review Complete 9th February 2015
- Adalimumab Humira® In combination with methotrexate for polyarticular juvenile idiopathic arthritis in children and adolescents (4-17yrs) in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate. Rapid Review Complete 2nd June 2011
- Adenuric Febuxostat® A xanthine oxidase inhibitor for the treatment of gout. Rapid Review Complete 8th December 2009
- Afatinib Giotrif® As monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). Rapid Review Complete 15th October 2013
- Aflibercept Eylea® For the treatment of neovascular (wet) age-related macular degeneration (AMD). Rapid Review Complete 21st December 2012
- Aflibercept Zaltrap® For the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. NCPE Assessment Process Complete 12th February 2014
- Agomelatine Valdoxan® For the treatment of major depressive disorder. NCPE Assessment Process Complete 3rd September 2009
- Alectinib Alecensa® For the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib. Rapid Review Complete 27th February 2017
- Alectinib Alecensa® For the first-line treatment of adult patients with ALK+ advanced NSCLC NCPE Assessment Process Complete 15th January 2019
- Alemtuzumab Lemtrada® For adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features NCPE Assessment Process Complete 25th June 2014
- Alirocumab Praluent® For the treatment of both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia NCPE Assessment Process Complete 6th June 2017
- Alogliptin Vipidia® For adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Rapid Review Complete 30th October 2013
20035 Alpelisib Piqray® Is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, human epidermal growth factor receptor 2 -negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy. NCPE Assessment Process Complete 21st December 2021
19038 Alutard SQ® honey bee and Alutard SQ® wasp venoms Alutard SQ® As allergy immunotherapies for patients with a documented history of generalised and/or systemic IgE-mediated allergic reactions due to sensitisation to honey bee venom (Apis mellifera) and wasp venom (Vespula spp.), respectively. Rapid Review Complete 11th March 2020
- Ambrisentan Volibris® For the treatment of patients with Functional Class II or III pulmonary arterial hypertension. Full HTA Assessment 4th July 2014
- Amifampridine Firdapse® For the treatment of Lambert Eaton Myasthenic Syndrome (LEMS) Rapid Review Complete 9th December 2011
20048 Amikacin Sulfate Arikayce® liposomal nebuliser dispersion For the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. NCPE Assessment Process Complete 18th December 2020
22004 Amivantamab Rybrevant® For the treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy. NCPE Assessment Process Complete 28th April 2023
- Amsacrine Amsidine® For the induction and maintenance of remission in acute leukaemia of adults. Rapid Review Complete 21st February 2017
22059 Anakinra Kineret® For the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) of at least 6 ng/ml. Rapid Review Complete 29th September 2022
20014 Andexanet alfa Ondexxya® For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.   NCPE Assessment Process Complete 27th May 2022
- Apalutamide Erleada® For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease. NCPE Assessment Process Complete 4th August 2020
20010 Apalutamide Erleada® For the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy. NCPE Assessment Process Complete 3rd March 2022
- Apixaban Eliquis® For treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Rapid Review Complete 13th August 2014
- Apixaban Eliquis® For the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery. NCPE Assessment Process Complete 19th June 2012
- Apixaban Eliquis® For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. NCPE Assessment Process Complete 21st May 2013
- Apremilast Otezla® For moderate to severe chronic plaque psoriasis. NCPE Assessment Process Complete 27th January 2016
- Apremilast Otezla® Alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. NCPE Assessment Process Complete 29th April 2016
- Argipressin acetate Embesin® For the treatment of moderate-to-severe atopic dermatitis in adults aged 18 years and older who are candidates for systemic therapy. Rapid Review Complete 11th October 2019
- Aripiprazole Abilify Maintena® For maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole Rapid Review Complete 7th August 2014
22053 Asciminib Scemblix® For the treatment of Adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in the chronic phase, who have previously been treated with two or more tyrosine kinase inhibitors. Rapid Review Complete 24th August 2022
- Asenapine Sycrest® For the treatment of moderate to severe manic episodes associated with biopolar 1 disorder in adults. Rapid Review Complete 6th September 2011
- Aspirin 81mg/Esomeprazole 20mg Axanum® Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers. Rapid Review Complete 16th May 2012
- Ataluren Translarna® For the treatment of DMD resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing. NCPE Assessment Process Complete 29th April 2016
- Atezolizumab Tecentriq® For the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum-containing chemotherapy. Rapid Review Complete 7th June 2019
- Atezolizumab Tecentriq® As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab. NCPE Assessment Process Complete 25th September 2018
21012 Atezolizumab Tecentriq® As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥50% tumour cells (TC) or ≥10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC. Rapid Review Complete 21st April 2021
22036 Atezolizumab Tecentriq® As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC. NCPE assessment ongoing 2nd June 2023
- Atezolizumab Tecentriq® In combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. NCPE Assessment Process Complete 1st September 2020